Haemophilia A and haemophilia B: molecular insights

This review focuses on selected areas that should interest both the scientist and the clinician alike: polymorphisms within the factor VIII and factor IX genes, their linkage, and their ethnic variation; a general assessment of mutations within both genes and a detailed inspection of the molecular pathology of certain mutations to illustrate the diverse cause–effect relations that exist; a summary of current knowledge on molecular aspects of inhibitor production; and an introduction to the new areas of factor VIII and factor IX catabolism. An appendix defining various terms encountered in the molecular genetics of the haemophilias is included, together with an appendix providing accession numbers and locus identification links for accessing gene and sequence information in the international nucleic acid databases.     

Identifying amino acid residues that influence plasma clearance of murine IgG1 fragments by site-directed mutagenesis

Site-directed mutagenesis has been used to change amino acid residues of a recombinant Fc-hinge fragment derived from the murine immunoglobulin (Ig)G1 molecule, and the effects of these mutations on the pharmacokinetics of the Fc-hinge fragment have been determined. Specifically, Ile-253, His-310 and Gln-311 of the CH2 domain and His-433 and Asn-434 of the CH3 domain have been changed. In the three dimensional structure of an antibody, these amino acids are in close proximity to each other at the CH2-CH3 domain interface. The mutated Fc-hinge fragments have been purified from recombinant Escherichia coli cells and their pharmacokinetic parameters determined in mice and compared with those of the wild-type Fc-hinge fragment. The results show that the site of the IgG1 molecule that controls the catabolic rate (the ‘catabolic site’) is located at the CH2-CH3 domain interface and overlaps with the Staphylococcal protein A binding site.     

Recently elucidated energy catabolism pathways provide opportunities for novel treatments in hepatocellular carcinoma

It has long been known that tumors depend on energy production pathways that are different from those of normal cells. These unique pathways require the expression and function of tumor-specific enzymes. Some of these glycolytic enzymes, as well as other modulators of tumor behavior, have recently been elucidated. In theory, inhibiting such enzymes or appropriately affecting such modulators should deprive tumors of energy, while leaving nontransformed cells unaffected. These factors include certain hexokinases that catalyze glycolysis in tumors and can be inhibited by 3-bromopyruvate. 2-deoxyglucose is another modulator that depletes hexokinase stores and cannot undergo further catabolism, thus depriving tumors of their energy source. Other enzymes or modulators are under scrutiny and have shown promise. Preliminary experiments on animals with hepatocellular carcinoma have indeed shown very encouraging results. It appears that modulating the energy production pathways of tumors is poised to become a substantial research area for cancer treatment. This review will focus on the energy production pathways of transformed cells, highlight the differences between transformed and normal cells in this regard and summarize recent experiments that take advantage of these disparities in cancer treatment.     

Leukotriene C4 contents,synthase and catabolic activity in human meningiomas

Abstract

Leukotriene has been proposed as a factor of tumour induced brain oedema. Independently of its size, meningioma occasionally shows various extents of peritumoural oedema. We investigated LTC₄ tissue contentsLTC₄ catabolic and synthetic activity in 12 human meningiomas and their correlation with peritumoural oedema was studied. LTC₄ contents were varied from 0.01 to 8.21 pg/mg tissue. When LTA4/ an unstable expoxide intermediate was incubated with tumour homogenate, LTC₄ was rapidly synthesized. However; LTC₄ levels generated by incubating LTA4 with each homogenate were much different in each case. Degradation of LTC₄ to LTD4, LTE4, and other polar materials was also rapid by incubation with tumour homogenates. Approximately 70% of added UC₄ was transformed to LTD4/ LTE4 nor 6-trans LTB4 diastereoisomers during 30 min incubation at 37 °C. The results suggested that there were significant LTC₄ tissue contents and LTC₄ synthetic and catabolic activity in meningiomas. Oedema index ranged from 1.0 (no peritumoural oedema) to 67.5. No significant correlationi, however', was observed not only between the LTC₄ tissue contents and LTC₄ synthetic or catabolic activities but also between each of these three parameters and peritumoural oedema. Thus, these results do not support a significant correlation of sulfidopeptide LTs with oedema formation in meningioma patients. Since leukotrienes are extremely unstable compounds, LTC₄ tissue contents should be carefully discussed along with a consideration of rapid LTC₄ synthesis and catabolism. Further role of leukotrienes in meningioma tissue should be studied.     

Role of Aggregatibacter actinomycetemcomitans in glutathione catabolism

Introduction:  Our previous studies demonstrated that three enzymes, γ-glutamyltransferase (GGT), cysteinylglycinase (CGase) and cystalysin, are required for the catabolism of glutathione to produce hydrogen sulfide (H₂S) in Treponema denticola . In this study, we examined glutathione catabolism in Aggregatibacter actinomycetemcomitans .
Methods:  The GGT and CGase of A. actinomycetemcomitans were determined by biological methods and GGT was characterized using a molecular biological approach.
Results:  A. actinomycetemcomitans showed GGT and CGase activity, but could not produce H₂S from glutathione. The addition of recombinant T. denticola cystalysin, an l -cysteine desulfhydrase, to whole cells of A. actinomycetemcomitans resulted in the production of H₂S from glutathione. Subsequently, we cloned A. actinomycetemcomitans GGT gene ( ggt ) and overexpressed the 63 kDa GGT protein. The recombinant A. actinomycetemcomitans GGT was purified and identified. The K _cat/ K _m of the recombinant GGT from N -γ- l -glutamyl-4-nitroaniline as substrate was 31/μ m /min. The activity of GGT was optimum at pH 6.9–7.1 and enhanced by thiol-containing compounds.
Conclusion:  The results demonstrated that A. actinomycetemcomitans had GGT and CGase activities and that the GGT was characterized. The possible role of A. actinomycetemcomitans in glutathione metabolism and H₂S production from oral bacteria was discussed.     

脂联素通过AMPK调节HepG2细胞中支链氨基酸的代谢

目的:探讨脂联素(APN)对HepG2细胞支链氨基酸(BCAA)分解代谢的影响及其作用机制。方法:将培养的HepG2细胞系随机分为对照组、APN组、APN+腺苷酸活化蛋白激酶(AMPK)抑制剂(Compound C,CpC)组(APN+CpC)组和AMPK激动剂(AICAR)组。用Western blot检测AMPK、P-AMPK、BCKD E1α(BCAA分解代谢过程中的关键酶,磷酸化时为失活状态)及P-BCKD E1α蛋白的表达,用ELISA方法检测培养HepG2细胞上清中BCAA的含量。结果:与对照组相比,APN组和AICAR组均可以显著上调细胞P-AMPK的水平(P0.05,P0.01),显著降低细胞p-BCKD E1α及上清中BCAA的水平(P0.05,P0.01)。与APN组比较,APN+CpC组,其细胞内PAMPK水平显著下降(P0.01),P-BCKD E1α及上清中BCAA的水平明显上升(分别为P0.05及P0.01)。结论:APN可显著促进HepG2细胞BCAA的分解代谢,其作用机制与AMPK磷酸化作用的上调相关。     

色氨酸分解代谢途径阻断对深海链霉菌ZH66次级代谢及生长的影响

【目的】以深海链霉菌Streptomyces somaliensis SCSIO ZH66为研究对象,通过阻断其色氨酸分解代谢途径,探究代谢产物与生长的变化。【方法】通过Blastp分析寻找S. somaliensis SCSIO ZH66基因组上编码色氨酸双加氧酶基因tdo(ORF0630和ORF6017),在前期阻断ORF0630的基础上采用PCR-targeting的策略阻断ORF6017,通过HPLC检测发酵产物的变化,并观察用不同培养基培养时突变株与野生株生长的差别。【结果】与野生株相比,突变株ZH66Δtdo不产生antimycins,但无其他次级代谢产物的变化。与此同时,ZH66Δtdo在MS平板上开始产生气生菌丝与孢子的时间均提前了12 h,在ISP-2液体培养基中生长对数期开始时间同样提前12 h。【结论】链霉菌S. somaliensis SCSIO ZH66中色氨酸分解代谢途径的阻断未促进其他可能以色氨酸为前体次级代谢产物的合成,而是促进了菌株的生长,为其他链霉菌中色氨酸分解代谢调控提供了借鉴。     

Serum concentration of L‐kynurenine predicts the clinical outcome of patients with diffuse large B‐cell lymphoma treated with R‐CHOP

Purpose: Introduction of rituximab has largely improved the prognosis of patients with diffuse large B‐cell lymphoma(DLBCL). Such change in therapeutic outcome necessitates the identification of additional prognostic factors to conventional indexes that have been validated for CHOP without rituximab. Indoleamine 2,3‐dioxygenase (IDO) exerts intense immunomodulatory effects because of enzymatic activities that catalyze the breakdown of the essential amino acid L‐tryptophan. The activity of IDO can be estimated by measuring the serum concentration of L ‐kynurenine. Here, we investigated the role of L ‐kynurenine as a prognostic marker in R‐CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone) therapy. Experimental design: Data from 73 consecutive patients treated with eight cycles of R‐CHOP or R‐THP (tetrahydropyranyl adriamycin)‐COP between December 2002 and March 2007 were analyzed. L ‐kynurenine concentrations in serum samples obtained at admission were measured by high‐performance liquid chromatography. Results: The median serum L ‐kynurenine level was 1.575 μm (range 0.537–9.588). The complete response (CR) rates of patients with L ‐kynurenine <1.5 and ≥1.5 μm were 83% and 61%, respectively (P < 0.05). The three‐yr overall survival (OS) rates for patients with L ‐kynurenine <1.5 and ≥1.5 μm were 89% and 58%, respectively (P < 0.005). In addition, higher age, poor performance status, elevated serum lactate dehydrogenase, and unfavorable as well as revised International Prognosis Index were significantly worse factors for CR rate and OS. Multivariate analyses revealed only L ‐kynurenine as an independent prognostic factor for OS. Conclusions: Serum L ‐kynurenine might be a novel prognostic factor to determine the treatment outcome of DLBCL with the R‐CHOP regimen.